1. Pharmacology of intracellular cytosine-arabinoside-5′-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes

   • U. Koehl
   • G. Hollatz
   • D. Schwabe

   Original Article 14 December 2006 Pages: 467 - 477

   

2. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

   • D. Ross Camidge
   • Mike Pemberton
   • Andrew Hughes

   Original Article 02 December 2006 Pages: 479 - 488

   

3. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma

   • Byeong-Bae Park
   • Joon Oh Park
   • Keunchil Park

   Original Article 30 March 2007 Pages: 489 - 494

   

4. Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA–IIIA non-small-cell lung cancer

   • Masafumi Kawamura
   • Keisuke Eguchi
   • Koichi Kobayashi

   Original Article 02 December 2006 Pages: 495 - 501

   

5. DPYD*2A mutation: the most common mutation associated with DPD deficiency

   • M. W. Saif
   • Hany Ezzeldin
   • Robert B. Diasio

   Original Article 13 December 2006 Pages: 503 - 507

   

6. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice

   • Anna M. E. Bruynzeel
   • Suzanne Vormer-Bonne
   • Wim J. F. van der Vijgh

   Original Article 20 December 2006 Pages: 509 - 514

7. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer

   • Ken-ichi Fujita
   • Yuichi Ando
   • Yasutsuna Sasaki

   Original Article 04 April 2007 Pages: 515 - 522

   

8. Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

   • Mario Campone
   • Jeany M. Rademaker-Lakhai
   • Jan H. M. Schellens

   Original Article 17 February 2007 Pages: 523 - 533

   

9. Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins

   • Maricarmen D. Planas-Silva
   • Kecia N. Hamilton

   Original Article 21 December 2006 Pages: 535 - 543

   

10. R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells

    • Elin Lindhagen
    • Sara Nissle
    • Anna Åleskog

    Original Article 22 December 2006 Pages: 545 - 553

    

11. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis

    • Kazuaki Niikura

    Original Article 23 December 2006 Pages: 555 - 562

    

12. Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates

    • Steve Y. Cho
    • Elizabeth Fox
    • Frank M. Balis

    Original Article 23 December 2006 Pages: 563 - 567

    

13. Influence of ketoconazole on the fecal and urinary disposition of docetaxel

    • Frederike K. Engels
    • Walter J. Loos
    • Jaap Verweij

    Original Article Open access 26 January 2007 Pages: 569 - 579

    

14. Trichosanthin down-regulated p210^Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562

    • Kunzhong Zhang
    • Jianhua Xu
    • Zhiqiang Zhang

    Original Article 14 April 2007 Pages: 581 - 587

    

15. Preclinical antitumor activity of the oral platinum analog satraplatin

    • Katja Wosikowski
    • Lou Lamphere
    • Maureen Caligiuri

    Original Article 31 May 2007 Pages: 589 - 600

    

16. Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer

    • Lin Run Wang
    • Ming Zhu Huang
    • Xiu Hua Wu

    Original Article 05 June 2007 Pages: 601 - 607

    

17. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

    • Christine Piard
    • Françoise Bressolle
    • Evelyne Jacqz-Aigrain

    Original Article 29 December 2006 Pages: 609 - 620

    

18. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia

    • Christine Plard
    • Françoise Bressolle
    • Evelyne Jacqz-Aigrain

    Erratum 04 July 2007 Pages: 621 - 621

19. Is rectal administration an alternative route for imatinib?

    • Nielka P. H. van Erp
    • Roos L. Oostendorp
    • Hans Gelderblom

    Short Communication Open access 08 February 2007 Pages: 623 - 624